2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

506. Bone Marrow Microenvironment: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Hemoglobinopathies, Infectious Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

4913 Distinct transcriptional and epigenetic remodeling of bone marrow stromal subsets in MPN is partially reversible by azacitidine

Iris Jade Bakker, MS, Stijn Fuchs2, Inge Snoeren3, Gerjanne Vroeg in de wei4, Tesa Klenovšek, MS5, Mashiro van Dal6, Stephani Schmitz7, Hector Tejeda Mora, PhD8, Ruben Boers, PhD9, Joost Gribnau, PhD10, Helene Gleitz, PhD11
1 Erasmus Medical Center, Rotterdam, Netherlands
2 Erasmus Medical Center, Rotterdam, Netherlands
3 Erasmus Medical Center, Rotterdam, Netherlands
4 Erasmus Medical Center, Rotterdam, Netherlands
5 Erasmus Medical Center, Rotterdam, Netherlands
6 Erasmus Medical Center, Rotterdam, Netherlands
7 Erasmus Medical Center, Rotterdam, Netherlands
8 Erasmus Medical Center, Rotterdam, Netherlands
9 Erasmus Medical Center, Rotterdam, Netherlands
10 Erasmus Medical Center, Rotterdam, Netherlands, Leiden University Medical Center, Leiden, Netherlands
11 Erasmus Medical Center, Rotterdam, Netherlands, University Hospital RWTH Aachen, Aachen, Germany

The bone marrow (BM) microenvironment, particularly stromal cell populations, is increasingly recognized as one of the drivers of disease progression and fibrosis in myeloproliferative neoplasms (MPN). Recent studies have shown that stromal populations within the BM microenvironment are heterogeneous and contribute differently to disease development. However, how these populations change during the transition from pre-fibrotic to fibrotic disease stages, and how these changes are regulated at the transcriptional and epigenetic level, remains largely unknown. We hypothesized that fibroblast (FB) and CXCL12 abundant reticular (CAR) stromal populations follow distinct temporal and molecular trajectories during disease progression, each contributing a discrete role to fibrotic transformation

To address this, we used the DCM-Time machine (DCM-TM) mouse model, which enables cell type-specific capture of active genes and enhancers combined with methylation-dependent sequencing (MeD-seq) to simultaneously profile CpG methylation. Together, these approaches allowed us to track transcriptional and epigenetic dynamics within specific stromal populations over the course of disease. We modeled bone marrow fibrosis by transplanting DCM-TM (DCM-Polr2b:m2rtTA) mice with control or thrombopoietin (ThPO)-overexpressing hematopoietic stem and progenitor cells (n=3-5 mice/group). To capture stromal changes preceding overt fibrosis, we isolated Sca1+ FB-enriched and Vcam1+ CAR cell-enriched stromal populations at early pre-fibrotic (grade 0, day 35) and later low-grade fibrotic (grade 1.25, day 63) disease stages post-transplant. 

Comparison of the FB and CAR populations revealed distinct transcriptional responses during disease progression. In the FB population, gene ontology analysis showed a temporal shift from cytoskeletal organization and wound healing at the pre-fibrotic stage toward myofibroblast differentiation and extracellular matrix organization during fibrosis, consistent with increased TGFβ pathway activity (PROGENy) already in the pre-fibrotic stage. In contrast, the CAR population showed progressive signaling pathway reprogramming, with enrichment for cytokines, Wnt and growth factor signaling alongside increased inferred inflammatory pathway activity as disease progressed. 

Transcriptional reprogramming in both cell populations was accompanied by aberrant CpG methylation, with 7-9% of differentially methylated regions/genes overlapping differentially expressed genes. This limited overlap indicates that disease-associated epigenetic remodeling largely occurs independently of direct transcriptional regulation, suggesting additional layers of gene regulatory control. 

Finally, we tested whether these molecular changes could be reversed by the hypomethylating agent 5-azacitidine (AZA), initiated either at the pre-fibrotic stage (two cycles) or at a later, more fibrotic stage (one cycle). Both regimens reduced splenic extramedullary hematopoiesis by 40% and bone marrow fibrosis and partially reversed disease-associated transcriptional and CpG methylation changes toward the healthy state. This reversal was reflected by consistent inverse correlations between disease-associated and AZA-induced changes across both stromal populations at both treatment timepoints, with strong reversal of transcriptional activity (ρ = -0.80 to -0.88) and more modest but consistent reversal of promoter CpG methylation (ρ = -0.46 to -0.71). These findings indicate that stromal remodeling remains pharmacologically responsive to AZA treatment even after fibrosis has developed. 

Together, these data show that FB and CAR populations follow distinct temporal and molecular trajectories that are already evident during the pre-fibrotic stage of MPN progression. FB cells progressively acquire a tissue-remodeling and fibrogenic transcriptional program, while CAR cells primarily undergo signaling reprogramming. Critically, both programs remain partially reversible with AZA treatment, underscoring the plasticity of the BM stromal niche and its potential as a therapeutic target in myelofibrosis. 

Iris Jade Bakker, MS: No relevant conflicts of interest to declare.